ArticleGlomerular diseases
Prognostic Value of Baseline and Early Proteinuria Changes in IgA Nephropathy: A US Cohort Study.
Article in Glomerular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Introduction: Proteinuria is a key marker in IgA nephropathy (IgAN). However, long-term thresholds and significance of early changes in proteinuria remains unclear in US populations. Methods: Retrospective cohort study of 745 adult patients with IgA nephropathy from the TriNetX US network (2015-2023). The baseline Time-average proteinuria (TAP) were calculated and categorized as <500, 500-1,000, 1,000-2,000, and >2,000 mg/g. Starting 1 year post diagnosis, the composite kidney failure outcome (sustained eGFR ≤15 mL/min/1.73 m Results: Out of 745 patients (mean age 43.5 [±16] years, 58% male, 68% White), a composite outcome occurred in 175 (23.5%) of patients over a median follow-up of 5.4 years (IQR: 3.2-7.2). Survival analysis showed 13.8% of patients with TAP <500 mg/g remained at risk of kidney failure by 8 years. Compared to TAP <500 mg/g, adjusted hazard ratios were significantly higher for TAP 1,000-2,000 mg/g (aHR 2.84; 95% CI: 1.66-4.85) and TAP >2,000 mg/g (aHR 5.68; 95% CI: 3.45-9.36); whereas TAP 500-1,000 mg/g was not significant after adjustment (aHR 1.69; 95% CI: 0.96-2.97). Higher baseline eGFR and white race were associated with better outcomes. Among 389 patients with follow up TAP data at the first-year observation period, each one-category reduction in TAP was associated with ∼40% lower risk of composite outcome, and ≥30% and ≥50% proteinuria reductions were associated with 62% and 66% lower risk of composite outcome, respectively. Conclusions: In US adults with IgA nephropathy, baseline proteinuria exceeding 1,000 mg/g identifies a high-risk group. Early proteinuria reductions - either by category (TAP) or percentage (≥30-50%) - strongly predict improved outcomes. This study supports use of proteinuria as a modifiable, treat-to-target surrogate for prognosis and treatment monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.